glp 1 receptors Glucagon-like peptide-1 receptor: mechanisms and advances in therapy The protective role of GLP-1

However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors

X (Twitter): @aniajastreboff

Another estimate puts this number at $471 billion

We believe they may become an important option for selected patients, particularly those with obesity, PCOS, and insulin resistance, she says

As the cost of these medications comes down and more people recognize the long-term benefits of obesity treatment, we may start to see insurance companies changing their approach

Identifying effective add-on therapies that improve glycemic control while minimizing hypoglycemia is a growing clinical priority